File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Sofosbuvir/Velpatasvir fixed dose combination for 12 weeks in hcv infected patients previously treated with placebo: results of the deferred treatment study (GS-US-342-1446 Study)

TitleSofosbuvir/Velpatasvir fixed dose combination for 12 weeks in hcv infected patients previously treated with placebo: results of the deferred treatment study (GS-US-342-1446 Study)
Authors
Issue Date2016
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S827-S828, abstract no. SAT-279 How to Cite?
AbstractBACKGROUND AND AIMS: The once-daily fixed-dose combination (FDC) tablet of sofosbuvir/velpatasvir (SOF/VEL) has demonstrated high efficacy in genotypes 1–6 HCV-infected patients when administered for 12 weeks. This analysis describes the safety and efficacy of SOF/VEL FDC in patients previously treated with SOF/VEL placebo in the phase 3 registrational, ASTRAL-1 study …
DescriptionPoster Presentations - Preliminary results of retrospective single center experience: no. SAT-279
Persistent Identifierhttp://hdl.handle.net/10722/234187
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570

 

DC FieldValueLanguage
dc.contributor.authorAsselah, T-
dc.contributor.authorShafran, S-
dc.contributor.authorBourgeois, S-
dc.contributor.authorLai, CL-
dc.contributor.authorCramp, M-
dc.contributor.authorMathurin, P-
dc.contributor.authorWillems, B-
dc.contributor.authorNguyen, MH-
dc.contributor.authorDavis, MN-
dc.contributor.authorHuang, KC-
dc.contributor.authorSvarovskaia, E-
dc.contributor.authorOsinusi, A-
dc.contributor.authorMcnally, J-
dc.contributor.authorBrainard, D-
dc.contributor.authorMcHutchison, J-
dc.contributor.authorShaikh, OS-
dc.contributor.authorTran, TT-
dc.date.accessioned2016-10-14T06:59:41Z-
dc.date.available2016-10-14T06:59:41Z-
dc.date.issued2016-
dc.identifier.citationThe International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S827-S828, abstract no. SAT-279-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/234187-
dc.descriptionPoster Presentations - Preliminary results of retrospective single center experience: no. SAT-279-
dc.description.abstractBACKGROUND AND AIMS: The once-daily fixed-dose combination (FDC) tablet of sofosbuvir/velpatasvir (SOF/VEL) has demonstrated high efficacy in genotypes 1–6 HCV-infected patients when administered for 12 weeks. This analysis describes the safety and efficacy of SOF/VEL FDC in patients previously treated with SOF/VEL placebo in the phase 3 registrational, ASTRAL-1 study …-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.rights© 2016 This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.titleSofosbuvir/Velpatasvir fixed dose combination for 12 weeks in hcv infected patients previously treated with placebo: results of the deferred treatment study (GS-US-342-1446 Study)-
dc.typeConference_Paper-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.doi10.1016/S0168-8278(16)01619-6-
dc.identifier.hkuros267701-
dc.identifier.volume64-
dc.identifier.issue2 suppl.-
dc.identifier.spageS827, abstract no. SAT-279-
dc.identifier.epageS828-
dc.publisher.placeThe Netherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats